Procedure
PD, death, Cancer
ADVERSE EVENT, ADVERSE EVENT, CANCER
Eligible patients were administrated camrelizumab (200 mg, day 1), irinotecan (65 mg/mEfficacy was assessed per RECIST 1.1 criteria after the first cycle, and every two cycles thereafter in both induction treatment phase and maintenance treatment phase. For patients without PD but who discontinued the treatment, efficacy was assessed every eight weeks until PD or death. Follow-up for survival was conducted every eight weeks until death or loss of follow-up. Adverse events (AEs) were recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 5.0).